CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Cut to Sell at ValuEngine

ValuEngine cut shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) from a hold rating to a sell rating in a research report released on Saturday, July 22nd.

Separately, Maxim Group reaffirmed a buy rating and set a $4.00 price objective on shares of CASI Pharmaceuticals in a research report on Friday, March 31st.

CASI Pharmaceuticals (NASDAQ:CASI) traded up 0.82% during midday trading on Friday, hitting $0.98. 22,700 shares of the stock traded hands. The company has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.16. CASI Pharmaceuticals has a 1-year low of $0.91 and a 1-year high of $1.76. The firm’s market cap is $58.99 million.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.01. Analysts predict that CASI Pharmaceuticals will post ($0.15) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Cut to Sell at ValuEngine” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/casi-pharmaceuticals-inc-nasdaqcasi-stock-rating-lowered-by-valuengine-updated-updated-updated.html.

A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Wellington Shields Capital Management LLC boosted its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 37.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 728,447 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the period. Wellington Shields Capital Management LLC owned 1.21% of CASI Pharmaceuticals worth $1,034,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.90% of the company’s stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about CASI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CASI Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit